I was going to ask what you meant by a pure trade, now i know. Yeah, I had my first batch at 2.36 pre market but wanted to do my dd before maxing out and buying trading shares. Thought about sellling at 2.69 but think it's got too solid of a pipeline, plus Monday could be big. It's worth a look + still close to option prices.
Yeah I don't want to pump it, but it does seem to have a solid pipeline with fairly soon binary announcements that move the biotechs. Do you see any obvious holes in their offerings patenright1? I always like to explore the weaknesses first and there is a lot to process with this stock. Nice buy in below 2.20. But can't recommend where to enter.
And the board is not like QCOR. You'll have to put up with this guy freeintheoc spamming OTOH abstral sales appear to be accelerating.
freeintheoc • Mar 5, 2014 2:42 A
YEA!! GO GALE!!
Sentiment: Strong Buy
Long term pphm is some of the myriad competition neuvax will face although pphm's new announcement would be supplementary to vaccines. Many companies are getting into the vaccine business and have platforms that can eventually be directed against a vast array of cancers. Then there is the falling knife thing. They didn't disclose they had hired a company to promote the stock and insider's sold.
So what: According to Peregrine's press release, it will be presenting data on three preclinical studies that highlight its immuno-oncology technology, which is aimed at training the body's immune system to recognize and attack cancer cells. The data presentations will revolve around Peregrine's phosphatidylserine-targeting antibodies. Phosphatidylserine (PS) is an immunosuppressive agent often found on the inside of healthy cells, but on the outside of cancer cells, allowing them to go undetected by the body's immune system. Peregrine's immunotherapy aims at suppressing this effect, allowing the body's immune system to recognize and eliminate these cancer cells.
Now what: Today's move could be a bit excessive considering that we're merely talking about a preclinical data presentation, but there's little denying that there's a ton of potential in Peregrine's immuno-oncology vaccine bavituximab, which also targets PS, and is currently in late-stage studies as a potential treatment for second-line non-small-cell lung cancer. Its midstage study produced a better than doubling in median overall survival to 12.1 months relative to the placebo, but its study was not without its own set of controversy. If Peregrine's phase 3 results deliver similarly impressive overall survival improvement, the company's immunotherapy solution could have explosive growth potential. Of course, investors should still keep in mind that small-cap biotechs have a very poor track record when it comes to cancer-drug success when considering Peregrine as an investmen
I bought a bunch after studying it, but I'm reducing the amount. The more I look at the Neuvax vaccine, with all the other cancer vaccines and various approaches to mount an immune response, I just can't see it as viable candidate. Tell me where I'm wrong but it clearly didn't meet its end point in the last trial and will at best be a weak sister facing soon, if not right away, strong competition.
Might get a quick pop if abstral sales are good at earnings, but there will surely be insider trading lawsuits and I think a cap will result..
I don't see any immediate impact from their third drug.
Make your case, I don't want to sell out too cheaply Plan to play the rise up to earnings..
Hell hire the ambulance chasers Beegz, leverage and fear are great equalizers. Screw any decorum. The attorney in breaking bad is a good model. You'd get free treatment if you weren't middle class. I no longer prescribe to guilt on issues like this when I see how much people get for free.
If you'll tell us how much you lost so far and stop posting crap like you shorted 3.5 million of QCOR in a week as an individual investor (how much cash would you have to have had for covering) I'll check in to it.
Then again are you sure you know anything about QCOR or FDA quality control?
Best strategy. As long as you can buy more later. That's what i did, but only because I think that this is going to blow up in citron's face. I expected it to go down until it was oversold about 60, but now this is going to change the whole dynamic.
Are you planning to cut lunch meat? You make it sound so dangerous and rough. I've got friends on the internet that are a lot tougher than you and they mean business when they type. So watch out, I may sic them on you.
Does it count as sex? or rape? or just internet sex? Can't brag about it to the boys if it's internet sex.
Congrats John. #$%$ i hate to think that from now on I'll have to hire a bunch of convicts to keep things fair. maybe Baghdad Bob is available or the POR trinity.
By the way: weeeeeeeeeeeeeeeee! weeeeeeeeeeeee! weeeeeeeeeee!
Did he really say that? He's stupid in that eventually a string of statements like this show criminality, basically why circumstantial evidence can be considered more powerful than direct evidence.
Children with infantile spasms die without medicine. ACTHAR is particularly effective in saving children afflicted with IS. Or maybe I'm wrong but my perspective is they often die with this condition if left untreated, which is certainly a very definitive biological assay for a drug's presence and effectiveness, if not a gruesome one. If there is no ACTHAR in the vial, and there probably has to be a rich miasma of concentrated drug at a high or at least effective dose to work, then we already know the patient will die, so the claim is ridiculous considering the number of children saved in such dramatic fashion.
Shorts used to claim it was ridiculous that ACTHAR could treat so many diseases effectively, that on its face it must be impossible, that only a magic elixir could do this, so longs were believing in the equivalent of fairy tales and unicorns. An idiotic posturing or ignorance of how wide ranging an immunosuppressant can be in treating various diseases. Is their argument now that ACTHAR is a placebo or that ACTHAR used to treat diseases other than infantile spasms is a placebo?
Anytime you read an ACTHAR patient forum the drug is highly praised. That's where you can often get the best perspective as to whether a drug is truly effective. Comparing forums for other immunosuppresants like anti TNF factors or steroids you see lots of side effects and inconsistent effectiveness relative to patients treated with ACTHAR.
Looks like its the RSI and we may have to wait until it gets back into the oversold area before we buy again. Scandalous.
Wonderful report. Market only looked at the inability to hit sales numbers, which everyone here knows is at least partially due to less MS flare ups in the winter.
100 shares of QCOR=7-8 thousand dollars 1000 shares of Qcor= seventy to eighty thousand dollars 10k shares of QCOR= seven to eight hundred thousand dollars. jo jo kell insane in the membrane claims he shorted at least 50 K of stock this week equal to over 3.5 million on one play. Hearing that he shorted again likely means the down draft will be short lived.. Every point QCOR goes up loses him 50k?
I didn't predict earnings, just took Don's word that earnings would pretty much be like last qtr's.
What I'm guessing is the market will focus mostly on QCOR's forward guidance. The forward outlook is stunning so my best guess is that the stock should recover in a fairly short time.
However there is the matter of the 1 year RSI being substantially oversold. Qcor has retraced substantially on more than one occasion when this happens.
Those are the two things that will battle for the direction of qQOR imho.
Gosh darn new kids. Might have to have a dance off or something to settle this important #$%$ contest.
It just seems odd after watching people contribute a year and a half of substantive information to see the neophytes' exploding egos.
I hope you plan to properly prostrate yourself next time you blow an earnings number QCORsam. Everybody does you know. I mean you're not really leaving any room for charity next time you get it wrong.
Press Release: Questcor Reports Fourth Quarter and Full Year 2013 Financial Results
4:01p ET February 25, 2014 (Dow Jones)
Press Release: Questcor Reports Fourth Quarter and Full Year 2013 Financial Results
Questcor Reports Fourth Quarter and Full Year 2013 Financial Results
- Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year -
- Fourth Quarter GAAP EPS of $1.44, Non-GAAP EPS of $1.67 up 53% -
- Full Year 2013 Net Sales $799 Million; Increase 57% Year-over-Year -
- Full Year GAAP EPS of $4.76, Non-GAAP EPS of $5.48 up 65% -
- Rheumatology Largest Growth Contributor -
- Approximately One Million Shares Repurchased in Fourth Quarter -
ANAHEIM, Calif., Feb. 25, 2014
ANAHEIM, Calif., Feb. 25, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2013.